Adoptive Immunotherapy for EBV-Associated Malignancies

  • Kenneth G. Lucas
  • J. Christian Barrett
Part of the Cancer Treatment and Research book series (CTAR, volume 101)

Abstract

The recognition of an increased risk of certain malignancies in immunocompromised individuals has led to a growing understanding of the role of the immune system in the surveillance for and prevention of neoplasms. This fact, combined with the limitations and toxicities associated with currently available cytotoxic agents, has provided the impetus to investigate alternative therapeutic approaches. Over the past decade there has been an increased interest in biologic approaches to augment the immune system in its antineoplastic efforts including the use of biologic agents (ie. interferons and interleukins), vaccines, and adoptive immunotherapy. This chapter will discuss aspects of the Epstein-Barr virus and the human immune response against EBV. The clinical role of adoptive immunotherapy in the treatment of EBV-induced malignancies will be presented, as well as the areas of current investigation.

Keywords

Toxicity Lymphoma Leukemia Influenza Sarcoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Henle G et al. Antibodies to epstein-barr virus in burkitt’s lymphoma and control groups. Journal of the National Cancer Institute 1969; 43(5): 1147–1157.PubMedGoogle Scholar
  2. 2.
    Diehl V, et al. Demonstration of a herpes group virus in cultures of peripheral leukocytes from a patient with infectious mononucleosis. Journal of Virology 1968; 2(7): 663–669.PubMedGoogle Scholar
  3. 3.
    Svedmyr E et al. Virologic, immunologic, and clinical observations on a patient during the incubation, acute, and convalescent phases of infectious mononucleosis. Clinical Immunology and Immunopathology 1984; 30(3): 437–450.PubMedCrossRefGoogle Scholar
  4. 4.
    Lewin N et al. Characterization of ebv-carrying b-cell populations in healthy seropositive individuals with regard to density, release of transforming virus, and spontaneous outgrowth. International Journal of Cancer 1987; 39(4): 472–476.CrossRefGoogle Scholar
  5. 5.
    Henle G, Henle W, and Diehl V. Relation of burkitt’s rumor-associated herpes-type virus to infectious mononucleosis. Proceedings of the National Academy of Sciences of the United States of America 1968; 59(1): 94–101.PubMedCrossRefGoogle Scholar
  6. 6.
    Klein G et al. EBV-determined nuclear antigen (ebna)-positive cells in the peripheral blood of infectious mononucleosis patients. International Journal of Cancer 1976; 17(1): 21–26.CrossRefGoogle Scholar
  7. 7.
    Miller G et al. Prolonged oropharyngeal excretion of epstein-barr virus after infectious mononucleosis. New England Journal of Medicine 1973; 288(5): 229–232.PubMedCrossRefGoogle Scholar
  8. 8.
    Strauch B et al. Oropharyngeal excretion of epstein-barr virus by renal transplant recipients and other patients treated with immunosuppressive drugs. Lancet 1974; 1(7851): 234–237.PubMedCrossRefGoogle Scholar
  9. 9.
    Gerber P et al. Association of eb-virus infection with the post-perfusion syndrome. Lancet 1969; 1(7595): 593–595.PubMedCrossRefGoogle Scholar
  10. 10.
    Kaye KM and Kieff E. Epstein-Barr virus. Infectious Diseases, 2nd Edition, SL Gorbach, JG Bartlett, and NR Blacklow, editors. WB Sanders Company, Philadelphia, 1998; 2067–2073.Google Scholar
  11. 11.
    Zinkernagel RM et al. MHC-Restricted cytotoxic T-Cell: studies on the biological role of polymorphic major transplantation antigens determining t-cell restriction specificity, function, and responsiveness. Advances in Immunology 1979; 27: 51–177.PubMedCrossRefGoogle Scholar
  12. 12.
    Townsend A et al. The epitopes of influenza nucleoprotein recognized by cytotoxic t-lymphocytes can be defined with short synthetic peptides. Cell 1986;44(6): 959–968.PubMedCrossRefGoogle Scholar
  13. 13.
    Townsend A et al. Antigen recognition by class i restricted t-lymphocytes. Annual Reviews in Immunology 1989; 7: 601–624.CrossRefGoogle Scholar
  14. 14.
    Rickinson AB et al. Cellular immunologic responses to infection by the virus. In the epstein barr virus: recent advances, MA Epstein and BG Achong, editors. William Heinemann Medical Books Ltd., London, 1986; 75–125.Google Scholar
  15. 15.
    Murray RJ et al. Identification of target antigens for the human cytotoxic t cell response to epstein-barr virus (ebv): implications for the immune control of ebv-positive malignancies. Journal of Experimental Medicine 1992;176(1): 157–168.PubMedCrossRefGoogle Scholar
  16. 16.
    Khanna R et al. Localization of epstein-barr virus cytotoxic t cell epitopes using recombinant vaccinia: implications for vaccine development. Journal of Experimental Medicine 1992; 176(1): 169–176.PubMedCrossRefGoogle Scholar
  17. 17.
    Klein G and Klein E. Epstein-barr virus and human lymphomas. In Canellos et al (editors) The Lymphomas, Philadelphia, Saunders Company 1998; 63–73.Google Scholar
  18. 18.
    Swinnen LJ et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody okt3 in cardiac-transplant recipients. New England Journal of Medicine 1990; 323(25): 1723–1728.PubMedCrossRefGoogle Scholar
  19. 19.
    Wilkinson AH et al. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azothioprine, and prednisone. Transplantation 1989; 47(2): 293–296.PubMedCrossRefGoogle Scholar
  20. 20.
    Crawford DH et al. Studies on the long-term t cell mediated immunity to epstein-barr virus in immunosuppressed renal allograft recipients. International Journal of Cancer 1981; 28(6): 705–709.CrossRefGoogle Scholar
  21. 21.
    Knowles DM et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85(2);552–565.PubMedGoogle Scholar
  22. 22.
    Locker J and Nalesnik M. Molecular genetic analysis of lymphoid tumors arising after organ transplantation. American Journal of Pathology 1989; 135(6);977–987.PubMedGoogle Scholar
  23. 23.
    Hjelle B et al. A poorly differentiated lymphoma of donor origin in a renal allograft recipient. Transplantation 1989; 47(6): 945–948.PubMedCrossRefGoogle Scholar
  24. 24.
    Gambacorta M et al. Malignant lymphoma in the recipient of a heart transplant from a donor with malignant lymphoma. Lymphoma Transplantation or De Novo Disease? Transplantation 1991; 151(4): 920–922.Google Scholar
  25. 25.
    Thomas JA et al. Immunohistology of epstein-barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation 1990; 49(5);944–953.PubMedCrossRefGoogle Scholar
  26. 26.
    Nalesnik MA et al. The pathology of posttransplant lymphoproliferative disorders occuring in the setting of cyclosporine a-prednisone immunosuppression. American Journal of Pathology 1988; 133(1): 173–192.PubMedGoogle Scholar
  27. 27.
    Perm I. Host origin of lymphomas in organ transplant recipients. Transplantation 1979; 27(3): 214.CrossRefGoogle Scholar
  28. 28.
    Randhawa PS et al. Epstein-barr virus-associated lymphoproliferative disease in a heart-lung allograft. Demonstration of host origin by restriction fragment-length polymorphism analysis. Transplantation 1990; 49(1): 126–130.PubMedCrossRefGoogle Scholar
  29. 29.
    Thomas JA et al. Immunohistology of epstein-barr virus-associated antigens in b-cell disorders from immunocompromised individuals. Transplantation 1990; 49(5): 944–953.PubMedCrossRefGoogle Scholar
  30. 30.
    Zutter MM et al. Epstein-barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72(2), 520–529.PubMedGoogle Scholar
  31. 31.
    List AF et al Lymphoproliferative diseases in immunocompromised hosts: the role of epstein-barr virus. Journal of Clinical Oncology 1987; 5(10): 1673–1689.PubMedGoogle Scholar
  32. 32.
    McGlave P et al. Unrelated donor bone marrow transplantation therapy for chronic myelogenous leukemia. Blood 1987; 70(3): 877–881.PubMedGoogle Scholar
  33. 33.
    Miller WJ et al. Molecular genetic rearrangements distinguish pre-and post-bone marrow transplantation lymphoproliferative processes. Blood 1987; 70(3): 882–885.PubMedGoogle Scholar
  34. 34.
    Shapiro RS et al. Epstein-barr virus associated b cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71(5): 1234–1243.PubMedGoogle Scholar
  35. 35.
    Antin JH et al. Selective depletion of bone marrow t lymphocytes with anti-cd5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991; 78(8): 2139–2149.PubMedGoogle Scholar
  36. 36.
    Schubach WH et al. A monoclonal immunoblastic sarcoma in donor cells bearing epstein-barr virus genomes following allogeneic marrow grafting for acute lymphoblastic leukemia. Blood 1982; 60(1): 180–187.PubMedGoogle Scholar
  37. 37.
    Martin PJ et al. Fatal epstein-barr virus-associated proliferation of donor b-cells after treatment of acute graft-versus-host disease with a murine anti-t-cell antibody. Annals of Internal Medicine 1984; 101(3): 310–315.PubMedGoogle Scholar
  38. 38.
    Lucas KG et al. The development of cellular immunity to epstein-barr virus after allogeneic bone marrow transplantation. Blood 1996; 87(6): 2594–2603.PubMedGoogle Scholar
  39. 39.
    Gossett TC et al. Immunoblastic sarcoma in donor cells after bone marrow transplantation. New England Journal of Medicine 1979; 300(16): 904–907.PubMedCrossRefGoogle Scholar
  40. 40.
    Bloom et al. Lymphoma of host origin in a marrow transplant recipient in remission of acute myeloid leukemia and receiving cyclosporin a. American Journal of Haematology 1985; 18(1): 73–83.CrossRefGoogle Scholar
  41. 41.
    Crawford DH et al. Epstein-barr virus infection and immunity in bone marrow transplant recipients. Transplantation 1986; 42(1): 50–54.PubMedCrossRefGoogle Scholar
  42. 42.
    Keever CA et al. Immune reconstitution following bone marrow transplantation: comparison of recipients of t-cell depleted marrow with recipients of conventional marrow grafts. Blood 1989; 73(5): 1340–1350.PubMedGoogle Scholar
  43. 43.
    Biggar RJ et al. Cancer trends among young single men in the seer registries of the united states. Presented at the International Conference on AIDS, Paris, June 1986.Google Scholar
  44. 44.
    Levine AM. Acquired immunodeficiency-related lymphoma. Blood 1992; 80(1): 8–20.PubMedGoogle Scholar
  45. 45.
    Hammer SM et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and cd4 cell counts of 22 per cubic millimeter or less. New England Journal of Medicine 1997; 337(11): 725–733.PubMedCrossRefGoogle Scholar
  46. 46.
    Buchbinder SP et al. Declines in aids incidence associated with highly active anti-retroviral therapy (Haart) are not reflected in ks and lymphoma incidence. Presented at the Second National AIDS Malignancy Conference, Bethesda, April 1998.Google Scholar
  47. 47.
    Jacobson LP. Impact of highly active anti-retroviral therapy on the incidence of malignancies among hiv-infected individuals. Presented at the Second National AIDS Malignancy Conference, Bethesda, April 1998.Google Scholar
  48. 48.
    Knowles DM and R Dalla-Favera. Aids-associated malignant lymphoma. In Broder et al (editors) Textbook of AIDS Medicine, Baltimore, Williams & Wilkins 1994; 431–463.Google Scholar
  49. 49.
    Hamilton-Dutoit SJ et al. Epstein-barr virus latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-hodgkin’s lymphoma. American Journal of Pathology 1993; 143(4): 1072–1085.PubMedGoogle Scholar
  50. 50.
    Forsyth PA et al. Biology and management of aids-associated primary central nervous system lymphomas. Hematology-Oncology Clinics of North America 1996; 10(5): 1125–1134.CrossRefGoogle Scholar
  51. 51.
    MacMahon EM et al. Epstein-Barr virus in AIDS-Related primary central nervous System Lymphomas. Lancet 1991; 338(8773): 969–973.PubMedCrossRefGoogle Scholar
  52. 52.
    Nakhleh RE et al. Central nervous system lymphomas. Immunohistochemical and Clinicopathologic Study of 26 Autopsy Cases. Archives of Pathology and Laboratory Medicine 1989; 113(9):, 1050–1056.PubMedGoogle Scholar
  53. 53.
    Camilleri-Broet S et al. AIDS-Related primary brain lymphomas: histopathologic and immunohistochemical study of 51 cases. Human Pathology 1997; 28(3): 367–374.PubMedCrossRefGoogle Scholar
  54. 54.
    Camilleri-Broet S et al. High expression of latent membrane protein 1 of epstein-barr virus and bcl-2 oncoprotein in acquired immunodeficiency syndrome-related primary brain lymphomas. Blood 1995; 86(2): 432–435.PubMedGoogle Scholar
  55. 55.
    Auperin I et al. Primary central nervous system malignant non-hodgkin’s lymphomas from hiv-infected and non-infected patients: expression of cellular surface proteins and epstein-barr viral markers. Neuropathology and Applied Neurobiology 1994; 20(3): 243–252.PubMedCrossRefGoogle Scholar
  56. 56.
    Kersten MJ et al. Epstein-barr virus-specific cytotoxic t cell responses in hiv-1 infection. Journal of Clinical Investigation 1997;99(7): 1525–1533.PubMedCrossRefGoogle Scholar
  57. 57.
    Reddehase MJ et al. Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. Journal of Virology 1985; 55(2): 264–273.PubMedGoogle Scholar
  58. 58.
    Reddehase MJ et al. Cd8-positve t-lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. Journal of Virology 1987; 61(10): 3102–3108.PubMedGoogle Scholar
  59. 59.
    Kolb HJ et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76(12): 2462–2465.PubMedGoogle Scholar
  60. 60.
    Porter DL et al.Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New England Journal of Medicine 1994; 330(2): 100–106.PubMedCrossRefGoogle Scholar
  61. 61.
    Walter EA et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of t-cell clones from the donor. New England Journal of Medicine 1995; 333(16): 1038–1044.PubMedCrossRefGoogle Scholar
  62. 62.
    Papadopoulos EB et al. Infusions of donor leukocytes to treat epstein-barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New England Journal of Medicine 1994; 330(17): 1185–1191.PubMedCrossRefGoogle Scholar
  63. 63.
    Heslop HE et al. Donor t-cells to treat EBV-associated lymphoma, (letter) New England Journal of Medicine 1994; 331(10): 679–680.PubMedCrossRefGoogle Scholar
  64. 64.
    Lucas KG et al. Semiquantitative epstein-barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998; 91(10): 3654–3661.PubMedGoogle Scholar
  65. 65.
    Rooney CM et al. Use of gene-modified virus specific t lymphocytes to control epstein-barr-virus-related lymphoproliferation. Lancet 1995; 345(8941): 9–13.PubMedCrossRefGoogle Scholar
  66. 66.
    Buchsbaum RJ et al. EBV-specific cytotoxic t lymphocytes protect against human EBV-associated lymphoma in scid mice. Immunology Letters 1996;52(2,3): 145–152.PubMedCrossRefGoogle Scholar
  67. 67.
    Heslop HE et al. Long-term restoration of immunity against epstein-barr virus infection by adoptive transfer of gene-modified virus-specific t lymphocytes. Nature Medicine 1996; 2(5): 551–555.PubMedCrossRefGoogle Scholar
  68. 68.
    Camoli P et al. Autologous ebv-specific cytotoxic t cells to treat EBV-associated post-transplant lymphoproliferative disease (PTLD). Blood 1997;90(10)suppl l(partl): 249a,abstract 1097.Google Scholar
  69. 69.
    Emanuel DJ et al. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation 1997;63(11): 1691–1694.PubMedCrossRefGoogle Scholar
  70. 70.
    Lemas MV et al. EBV-specific cd4+ t cell responses in immune compromised HIV+ Individuals with Lymphoma. Blood 1997; 90(10)suppl 1(part 1): 134a, abstract 589.Google Scholar
  71. 71.
    McGowan JP et al. Long-term remission of AIDS-related primary central nervous system lymphoma (PCNSL) with the use of highly active antiretro viral therapy (HA ART). 2nd National AIDS Malignancy Conference, Bethesda, Maryland. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998; 17(4): A30, abstract 74.CrossRefGoogle Scholar
  72. 72.
    Wheatley GH et al. Adoptive immunotherapy using autologous EBV-specific cytotoxic t-lymphocytes in an HIV-infected patient with refractory epstein-barr virus expressing b-cell lymphoma. 1st National AIDS Malignancy Conference, Bethesda, Maryland. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1997; 14(4): A53, abstract 147.CrossRefGoogle Scholar
  73. 73.
    Lemas MV et al. Large-scale expansions of ebv-specific cytotoxic t lymphocyte (ctl) lines lyse EBV-infected haploidentical target cells but not uninfected autologous or hapoloidentical cells. Blood 1997; 90(10)suppl 1(part 1): 134a–135a, abstract 590.Google Scholar
  74. 74.
    Lavi E and Way Q. The protective role of cytotoxic t cells and interferon against coronavirus invasion of the brain. Talbot and Levy (editors). Corona and Related Viruses 1995.Google Scholar
  75. 75.
    Stohlman S et al. JHM virus-specific cytotoxic t-cells derived from the central nervous system. Laude and Vautherot (editors). Coronaviruses 1994.Google Scholar
  76. 76.
    Hudson SL and Streilein JW. Functional cytotoxic T cells are associated with focal lesions in the brains of SJL mice with experimental herpes simplex encephalitis. Journal of Immunology 1994; 152(11): 5540–5547.Google Scholar
  77. 77.
    Matloubian M et al. CD4+ T cells are required to sustain CD8+ cytotoxic T cell responses during chronic viral infection. Journal of Virology 1994; 68(12): 8056–8063.PubMedGoogle Scholar
  78. 78.
    Niedobitek G et al. Heterogeneous expression of epstein-barr virus latent proteins in endemic burkitt’s lymphoma. Blood 1995; 86(2): 659–665.PubMedGoogle Scholar
  79. 79.
    Shiramizu B et al. Patterns of chromosomal breakpoint locations in burkitt’s lymphoma: relevance to geography and epstein-barr virus association. Blood 1991; 77(7): 1516–1526.PubMedGoogle Scholar
  80. 80.
    Rooney CM et al. Epstein-barr virus-positive burkitt’s lymphoma cells not recognized by virus-specific t-cell surveillance. Nature 1985; 317(6038): 629–631.PubMedCrossRefGoogle Scholar
  81. 81.
    Gregory CD et al. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in epstein-barr virus-positive burkitt’s lymphoma underlies tumor cell escape from virus-specific T cell surveillance. Journal of Experimental Medicine 1988; 167(6): 1811–1824.PubMedCrossRefGoogle Scholar
  82. 82.
    Woisetschlaeger M et al. Mutually exclusive use of viral promoters in epstein-barr virus latently infected lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 1989; 86(17): 6489–6502.CrossRefGoogle Scholar
  83. 83.
    Sample J et al. The epstein-barr virus nuclear protein 1 promoter active in type 1 latency is autoregulated. Journal of Virology 1992; 66(80: 4654–4661.PubMedGoogle Scholar
  84. 84.
    Weiss LM et al. Epstein-barr viral DNA in tissues of hodgkin’s disease. American Journal of Pathology 1987; 129(1): 86–91.PubMedGoogle Scholar
  85. 85.
    Weiss LM et al. Detection of epstein-barr viral genomes in reed-sternberg cells of hodgkin’s disease. New England Journal of Medicine 1989; 320(8): 502–506.PubMedCrossRefGoogle Scholar
  86. 86.
    Anagnostopoulos I et al. Demonstration of monoclonal EBV genomes in hodgkin’s disease and KI-1-positive anaplastic large cell lymphoma by combined southern blot and in situ hybridization. Blood 1989; 74(2): 810–816.PubMedGoogle Scholar
  87. 87.
    Wu TC et al. Detection of EBV gene expression in reed-sternberg cells of hodgkin’s disease. International Journal of Cancer 1990; 46(5): 801–804.CrossRefGoogle Scholar
  88. 88.
    Weiss LM et al. Epstein-Barr virus and hodgkin’s disease. A correlative in situ hybridization and polymerase chain reaction study. American Journal of Pathology 1991; 139(6): 1259–1265.PubMedGoogle Scholar
  89. 89.
    Herbst H et al. High incidence of epstein-barr virus genomes in hodgkin’s disease. American Journal of Pathology 1990; 137(1): 13–18.PubMedGoogle Scholar
  90. 90.
    Herbst H et al. Distribution and phenotype of epstein-barr virus-harboring cells in hodgkin’s disease. Blood 1992; 80(2): 484–491.PubMedGoogle Scholar
  91. 91.
    Boiocchi M et al. Association of epstein-barr virus genome with mixed cellularity and cellular phase nodular sclerosis hodgkin’s disease subtypes. Annals of Oncology 1992; 3(4): 307–310.PubMedGoogle Scholar
  92. 92.
    Herbst H et al. Epstein-barr virus latent membrane protein expression in hodgkin and Reed-Sternberg cells. Proceedings of the National Academy of Sciences of the United States of America 1991; 88(ll): 4766–4770.PubMedCrossRefGoogle Scholar
  93. 93.
    Pallesen G et al. Expression of epstein-barr virus latent gene products in tumour cells of hodgkin’s disease. Lancet 1991; 337(8737): 320–322.PubMedCrossRefGoogle Scholar
  94. 94.
    Poppema S and Visser L. Absence of hla class i expression by reedsternberg cells. American Journal of Pathology 1994; 145(1): 37–41.PubMedGoogle Scholar
  95. 95.
    Frisan T et al. Local suppression of epstein-barr virus (EBV)-specific cytotoxicity in biopsies of EBV-Positive hodgkin’s disease. Blood 1995; 86(4): 1493–1501.PubMedGoogle Scholar
  96. 96.
    Sing AP et al. Isolation of epstein-barr virus (EBV)-specific cytotoxic t lymphocytes that Lyse Reed-Sternberg cells: implications for immunemediated therapy of EBV+ hodgkin’s disease. Blood 1997; 89(6): 1978–1986.PubMedGoogle Scholar
  97. 97.
    Rentier CR et al. Cure of disseminated xenografted human hodgkin’s tumors by bispecific monoclonal antibodies and human T cells: the role of human t-cell subsets in a preclinical model. Blood 1996; 87(7): 2930–2937.Google Scholar
  98. 98.
    Lee SP et al. Conserved epitopes within ebv latent membrane protein 2: a potential target for ctl-based tumor therapy. Journal of Immunology 1997; 158(7): 3325–3334.Google Scholar
  99. 99.
    Romani N et al. Proliferating dendritic cell progenitors in human blood. Journal of Experimental Medicine 1994; 180(1): 83–93.PubMedCrossRefGoogle Scholar
  100. 100.
    Roskrow MA et al. Genetically modified dendritic cells generate primary and memory tumor antigen-specific cytotoxic t lymphocytes. Blood 1996; 88(10)suppl 1(part1): 87a,abstract 337.Google Scholar
  101. 101.
    Wiryana P et al. Augmentation of cell-mediated immunotherapy against herpes simplex virus by interleukins: comparison of in vivo effects of IL-2 and IL-7 on adoptively transferred T cells. Vaccine 1997; 15(5): 561–563.PubMedCrossRefGoogle Scholar
  102. 102.
    Hombach A et al. Specific activation of resting t cells against ca 19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody. Journal of Immunotherapy 1997; 20(5): 325–333.PubMedCrossRefGoogle Scholar
  103. 103.
    Mavilo F et al. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 1994; 83(7): 1988–1997.Google Scholar
  104. 104.
    Tiberghien P et al. Ganciclovir treatment of herpes simplex thymidine kinase transduced primary t lymphocytes: an approach for specific in vivo donor t-cell depletion after bone marrow transplantation? Blood 1994; 84(4): 1333–1341.PubMedGoogle Scholar
  105. 105.
    Riddell SR et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Medicine 1996; 29(2): 216–223.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Kenneth G. Lucas
    • 1
  • J. Christian Barrett
    • 1
  1. 1.University of Alabama-BirminghamBirminghamUK

Personalised recommendations